Sutro Biopharma, Inc. (STRO)

Market Cap	172.74M +54.0%
Revenue (ttm)	105.65M -34.4%
Net Income	-216.77M
EPS	-25.88
Shares Out	8.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,983
Open	20.76
Previous Close	21.12
Day's Range	20.18 - 21.63
52-Week Range	n/a
Beta	1.48
Analysts	Hold
Price Target	18.50 (-8.82%)
Earnings Date	May 7, 2026

About STRO

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 178
• Stock Exchange: NASDAQ
• Ticker Symbol: STRO
• Website: https://www.sutrobio.com

Financial Performance

In 2024, Sutro Biopharma's revenue was $62.04 million, a decrease of -59.64% compared to the previous year's $153.73 million. Losses were -$227.46 million, 113.0% more than in 2023.

Analyst Summary

According to 6 analysts, the average rating for STRO stock is "Hold." The 12-month stock price target is $18.5, which is a decrease of -8.82% from the latest price.

Price Target

$18.5

(-8.82% downside)

Analyst Consensus: Hold